TAK-285 化学構造
分子量: 547.96

品質と確認

Quality Control & MSDS

製品情報

製品の説明

生物活性

情報 TAK-285は、17nMと23nMのIC50による新しい二重HER2とEGFR阻害剤です。
目標 HER2 EGFR
IC50 17 nM 23 nM [1]
In vitro試験 Among the 34 kinases tested, TAK-285 only significantly inhibits HER4 with IC50 of 260 nM, slightly inhibits MEK1, MEK5, c-Met, Aurora B, Lck, CSK, and Lyn B with IC50 of 1.1 μM, 5.7 μM, 4.2 μM, 1.7 μM, 2.4 μM, 4.7 μM, and 5.2 μM, respectively, and displays no activity against other kinases with IC50 of >10 μM. TAK-285 shows significant growth inhibitory activity against BT-474 cells (HER2-overexpressing human breast cancer cell line) with GI50 of 17 nM. [1] Compared with SYR127063 a potent inhibitor of HER2, TAK-285 displays similar in vitro potency against HER2 and EGFR. Compared with the full cytoplasmic domains of the wild-type proteins, the mutations and shortened boundaries used for structure determination of HER2-KD and EGFR-KD do not significantly change the inhibitory activity (IC50) of TAK-285. TAK-285 binds to the inactive conformation of EGFR, and shows a similar binding mode with lapatinib in the active site. [2]
In vivo試験 The oral bioavailability of TAK-285 is 97.7% in rats and 72.2% in mice at a dose of 50 mg/kg. Oral administration of TAK-285 at 100 mg/kg twice daily for 14 days displays significant antitumor efficacy in the HER2-overexpressing BT-474 tumor xenograft mouse model with tumor/control (T/C) ratio of 29%, without affecting body weight. Similar to the BT-474 model, TAK-285 exhibits dose-dependent tumor growth inhibition of 4-1ST (HER2-overexpressing human gastric cancer tumor) xenografts in mice, with T/C of 44% and 11% at doses of 50 mg/kg and 100 mg/kg, twice daily, respectively, without significant body weight loss in mice. Furthermore, TAK-285 treatment induces dose-dependent growth inhibition of 4-1ST tumors in rats with T/C of 38% and 14% at doses of 6.25 mg/kg and 12.5 mg/kg, and, particularly noteworthy, tumor regression with T/C of -12% and -16% at doses of 25 mg/kg and 50 mg/kg, respectively. [1] After oral administration of TAK-285, a significant amount of TAK-285 is present in the brain of rats in pharmacologically active, unbound form (approximately 20% of its free plasma level), indicating that TAK-285 has a potential in the therapy of CNS malignancies/metastases. [3]
臨床試験 A Phase I study of TAK-285 in patients with advanced cancer has been completed.
特集

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

HER2 and EGFR kinase assay The cytoplasmic domain (amino acids 676-1255) of human HER2 and the cytoplasmic domain (amino acids 669-1210) of human EGFR are expressed as N-terminal peptide (DYKDDDD)-tagged protein using a baculovirus expression system. The expressed HER2 kinase and EGFR kinase are purified by anti-FLAG M2 affinity gel. The EGFR and HER2 kinase assays are performed using radiolabeled [γ-32P]ATP in 96-well plates. The kinase reactions are performed in 50 mM Tris-HCl (pH 7.5), 5 mM MnCl2, 0.01% Tween 20, and 2 mM DTT containing 0.9 uCi of [γ-32P]ATP per reaction, 50 μM ATP, 5 ug/mL poly(Glu)-Tyr (4:1), and each purified cytoplasmic domain (0.25 μg/mL EGFR or HER2) in a total volume of 50 μL. To measure the IC50 value for enzyme inhibition, Increasing concentrations of TAK-285 are incubated with the enzyme for 5 minutes prior to the reaction at room temperature. The kinase reactions are initiated by adding ATP. After 10 minutes at room temperature, the reactions are stopped by the addition of 10% (final concentration) trichloroacetic acid. The γ-32P phosphorylated proteins are filtrated in a harvest plate with a cell harvester and washed free of [γ-32P]ATP with 3% phosphoric acid. The plates are dried followed by the addition of 25 μL of MicroScint0. The radioactivity is counted by a TopCount scintillation counter. IC50 values are calculated by nonlinear regression analysis of the percent inhibitions.

細胞アッセイ: [1]

細胞系 BT-474
濃度 Dissolved in DMSO, final concentrations ~10 μM
処理時間 5 days
方法 The cells are treated continuously with various concentrations of TAK-285 for 5 days. The live cell numbers are counted with a particle analyzer.

動物実験: [1]

動物モデル Female BALB/c nu/nu mice bearing BT-474 or 4-1ST xenografts, and female nude rats (F344/N Jcl-rnu) bearing 4-1ST xenografts
製剤 Suspended in 0.5% (w/v) methylcellulose solution
投薬量 ~100 mg/kg/day
管理 Orally twice daily
1

参考

化学情報

Download TAK-285 SDF
分子量 547.96
化学式

C26H25ClF3N5O3

CAS No. 871026-44-7
別名 N/A
溶解度 (25°C)
  • DMSO 110 mg/mL
  • 水 <1 mg/mL
  • エタノール 54 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 N-(2-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide

研究分野

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related EGFR 阻害剤

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992)は不可逆的にEGF受容体/ HER2含むEGF受容体を抑制、 EGFR L858R , EGFR L858R/T790M と HER2を作用すると、 IC50がそれぞれ0.5 nM, 0.4 nM, 10 nM, 14 nMとなる。

  • Canertinib (CI-1033)

    Canertinib (CI-1033) は有効的に チロシンキナーゼを抑制で、 EGFR と erbB2 を作用する時IC50 はそれぞれ 1.5 nM と 9.0 nMになる.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744)は、2nMのIC50によるHER1/EGFR阻害剤です。

  • Gefitinib (ZD1839)

    Gefitinib (ZD1839) は、NR6wtEGFRとNR6W細胞のTyr1173、Tyr992、Tyr1173とTyr992のためのEGFR阻害剤で、IC50 がそれぞれ 37 nM、 37nM、 26 nM 、57 nMです。

  • Lapatinib (GW-572016) Ditosylate

    Lapatinib (GW-572016) Ditosylateは有効EGFRとErbB2阻害剤、IC50それぞれ10.8と9.2nM。

  • AC480 (BMS-599626)

    AC480 (BMS-599626)は、HER1とHER2の選択的で口で有効な阻害剤で、IC50 がそれぞれ 20 nM と 30 nMです。

  • PD153035 HCl

    PD153035 HClは、EGFRの強力で特定の阻害剤で、Ki と IC50 がそれぞれ 5.2 pM と 29 pMです。

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42)は、EGFRの選択的な阻害剤、ErbB2とJAK2で、IC50 がそれぞれ 0.1 μM、 13.5 μM、 and ~10 μMです。

  • CP-724714

    CP-724714は、10nMのIC50によるerbB2の強力な、選択的な阻害剤です。

  • WZ3146

    WZ3146は、EGFR(L858R)とEGFR(E746_A750)の変異体選択元に戻らない阻害剤で、IC50 がそれぞれ 2 nM と 2 nMです。

最近見られたアイテム

Tags: TAK-285を買う | TAK-285供給者 | TAK-285を購入する | TAK-285費用 | TAK-285生産者 | オーダーTAK-285 | TAK-285代理店
お問い合わせ